Karyopharm Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

• Karyopharm Therapeutics Inc KPTI reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended in March, lower than the same quarter last year, when the company reported EPS of -30 cents. The mean expectation of seven analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -37 cents to -28 cents per share.

• Revenue fell 14.4% to $33.13 million from a year ago; analysts expected $34.47 million.

• Karyopharm Therapeutics Inc's reported EPS for the quarter was a loss of 32 cents​.

• The company reported a quarterly loss of $37.36 million.

• Karyopharm Therapeutics Inc shares had fallen by 27.2% this quarter and gained 27.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 11.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Karyopharm Therapeutics Inc is $5.00

This summary was machine generated from LSEG data May 8 at 02:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)